The Safety and Efficacy of Angiotensin II Receptor Blockers (ARBs) in Diabetic Patients with Advanced Chronic Kidney Disease

Safety and Efficiency of Angiotensin II Receptor Blockers (ARBs) in Diabetic Patients with Advanced Chronic Kidney Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210526006

Enrollment

165

Registered

2021-05-26

Start date

2021-06-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with advanced chronic kidney disease (CKD) who have newly received ARBs chronic kidney disease, diabetes mellitus, angiotensin II receptor blockers, renin-angiotensin system inhibitors

Interventions

Diabetic patients who newly start treatment with any ARBs during eGFR less than 30 ml/min/1.73m2,Diabetic patients who do not receive any ACEi/ARBs during eGFR less than 30 ml/min/1.73m2

Treatment,Treatment

ARBs group,Control group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with diabetes mellitus and advanced CKD, defines as estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2 will be included. The patients who newly start treatment with any ARBs during eGFR less than 30 ml/min/1.73m2 will be compared with patients who do not receive any ACEi/ARBs.

Exclusion criteria

Exclusion criteria: 1. age of < 18 years old, 2. eGFR < 6 ml/min/1.73 m2, 3. currently on renal replacement therapy, 4. patients who have currently received ACEi/ARBs before the cohort entry, 5. patients whose medical data could not be accessed.

Design outcomes

Primary

Measure	Time frame
time to the first event of composite major adverse kidney events (MAKE) including a doubling serum creatinine level, renal replacement therapy, and death. 36 months after the cohort entry month	—

Secondary

Measure	Time frame
time to the first event of major adverse cardiovascular events (MACE) that included non-fatal myocardial ischemia, non-fatal stroke, and death 36 months after the cohort entry month,time to the first event of hospitalization heart failure 36 months after the cohort entry month,time to the first event of eGFR decline more than 30% from baseline 36 months after the cohort entry month,eGFR decline overtime 36 months after the cohort entry ml/min/month,time to the first event of hyperkalemia 36 months after the cohort entry month	—

Measure

Time frame

time to the first event of major adverse cardiovascular events (MACE) that included non-fatal myocardial ischemia, non-fatal stroke, and death 36 months after the cohort entry month,time to the first event of hospitalization heart failure 36 months after the cohort entry month,time to the first event of eGFR decline more than 30% from baseline 36 months after the cohort entry month,eGFR decline overtime 36 months after the cohort entry ml/min/month,time to the first event of hyperkalemia 36 months after the cohort entry month

—

Countries

Thailand

Contacts

Public ContactWiranan Wattanakul

Thammasat University Hospital

cherrychemsa@gmail.com66819535082

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026